Zacks Investment Research lowered shares of PRA Health Sciences (NASDAQ:PRAH) from a buy rating to a hold rating in a research note published on Thursday morning.
According to Zacks, “PRA Health Sciences, Inc. operates as a global contract research organizations providing outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in the areas of cardio-metabolic, biosimilars, infectious diseases, immunology, neurology and psychiatry, oncology and hematology, rare diseases, and respiratory needs. The Company engages in bioanalytical laboratory, clinical pharmacology, clinical development, strategic solutions, post marketing research, clinical informatics, clinical diagnostics, and safety and risk management activities. PRA Health Sciences, Inc. is based in Raleigh, North Carolina. “
PRAH has been the topic of several other research reports. SunTrust Banks restated a buy rating and issued a $101.00 price objective on shares of PRA Health Sciences in a research note on Friday, October 27th. KeyCorp restated a buy rating and issued a $93.00 price objective (up previously from $86.00) on shares of PRA Health Sciences in a research note on Monday, October 30th. Mizuho set a $87.00 target price on PRA Health Sciences and gave the stock a buy rating in a research note on Friday, December 1st. Robert W. Baird reiterated a buy rating and set a $88.00 target price on shares of PRA Health Sciences in a research note on Monday, October 9th. Finally, BidaskClub lowered PRA Health Sciences from a strong-buy rating to a buy rating in a research note on Friday, January 5th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $91.85.
PRA Health Sciences (PRAH) traded up $0.61 during trading hours on Thursday, reaching $93.50. The company’s stock had a trading volume of 508,096 shares, compared to its average volume of 333,225. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 1.38. The company has a market capitalization of $5,886.41, a price-to-earnings ratio of 52.23, a price-to-earnings-growth ratio of 1.29 and a beta of 0.41. PRA Health Sciences has a 12-month low of $54.08 and a 12-month high of $94.28.
PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $0.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.03. The firm had revenue of $494.55 million for the quarter, compared to analyst estimates of $477.89 million. PRA Health Sciences had a return on equity of 21.66% and a net margin of 5.64%. The business’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.64 earnings per share. equities research analysts forecast that PRA Health Sciences will post 3.2 earnings per share for the current fiscal year.
In other news, EVP David W. Dockhorn sold 72,850 shares of the stock in a transaction that occurred on Friday, December 28th. The stock was sold at an average price of $90.83, for a total transaction of $6,616,965.50. Following the transaction, the executive vice president now owns 72,850 shares in the company, valued at $6,616,965.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Matthew P. Young sold 5,115 shares of the stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $79.90, for a total value of $408,688.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 217,815 shares of company stock worth $19,690,710. 2.10% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in PRA Health Sciences by 12.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after acquiring an additional 160 shares during the period. Los Angeles Capital Management & Equity Research Inc. increased its stake in PRA Health Sciences by 1.9% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 8,505 shares of the medical research company’s stock worth $638,000 after acquiring an additional 160 shares during the period. Zacks Investment Management increased its stake in PRA Health Sciences by 1.3% during the 2nd quarter. Zacks Investment Management now owns 48,885 shares of the medical research company’s stock worth $3,667,000 after acquiring an additional 614 shares during the period. First Bank & Trust increased its stake in PRA Health Sciences by 30.0% during the 4th quarter. First Bank & Trust now owns 3,259 shares of the medical research company’s stock worth $297,000 after acquiring an additional 752 shares during the period. Finally, Carroll Financial Associates Inc. increased its stake in PRA Health Sciences by 127.4% during the 3rd quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock worth $112,000 after acquiring an additional 790 shares during the period. Hedge funds and other institutional investors own 98.23% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “PRA Health Sciences (PRAH) Downgraded by Zacks Investment Research to Hold” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/01/21/pra-health-sciences-prah-downgraded-by-zacks-investment-research-to-hold.html.
About PRA Health Sciences
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.